News and Announcements
Millenium Kapital appoint new Non Executive Director in lead up to IPO
- Published January 30, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
MKL is pleased to announce that it has appointed Steve Ledger as its Non-Executive Director in the lead up its IPO.
Steve is a commercially focused professional with vast experience throughout Australia, the UK and the US. He is the Founder of Ledger Corporate Chartered Accountants which he established in 2003.
The MKL Board going into the IPO will now consist of Mr Cyril D’Silva as Executive Chairman, Miss Lina Tirado as CEO and Mr Steve Ledger as its Non- Executive Director.
The company is still in its Pre IPO stage and its current raising is at 2p
About Millenium Kapital Ltd
Millenium Kapital Ltd (MKL) is currently in pre-IPO stage where it is raising working capital at 2 pence. Its intention is to float MKL at 3 pence with a maximum of 100 million shares on issue and is targeting to raise a total of £1,450,000, which will include IPO and pre-IPO expenses.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
